Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Safety and PK Study of PIPE-307 in Healthy Volunteers
NCT04725175Phase 1Completed
- Sponsor
- Contineum Therapeutics
- Start
- Feb 2021
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in multiple sclerosis (MS) comparing PIPE-307 with Placebo (2 arms). Primary endpoint: Treatment-Emergent Adverse Events. Started Feb 2021; status: completed.
02
Drugs
PIPE-307
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT04725175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04725175.